Newsfeeds - Spark Newswire

4 minute read

Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank

March 11, 3:27 PM

The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the company’s Silicon Valley Bank.

AMBA

2 minute read

Earnings

Mirum Pharmaceuticals Earnings Perspective: Return On Capital Employed

By Benzinga Insights

March 10, 10:50 AM

Benzinga Pro data, Mirum Pharmaceuticals (NASDAQ:MIRM) reported Q4 sales of $27.91 million. Earnings fell to a loss of…

MIRM

1 minute read

HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $61 Price Target

By Benzinga Newsdesk

March 9, 10:12 AM

HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $61 price target.

MIRM

1 minute read

Raymond James Maintains Strong Buy on Mirum Pharmaceuticals, Lowers Price Target to $83

By Benzinga Newsdesk

March 9, 8:08 AM

Raymond James analyst Steven Seedhouse maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Strong Buy and lowers the price target from $84 to $83.

MIRM

1 minute read

Mirum Pharmaceuticals Q4 EPS $(0.99) Beats $(1.02) Estimate, Sales $27.91M Beat $24.57M Estimate

By Benzinga Newsdesk

March 8, 5:13 PM

Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.99) per share which beat the analyst consensus estimate of $(1.02) by 2.94 percent. This is a 40 percent increase over losses of $(1.65) per share from

MIRM

6 minute read

Earnings

Earnings Scheduled For March 8, 2023

By Benzinga Insights

March 8, 5:42 AM

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.

ABM

1 minute read

HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Lowers Price Target to $61

By Benzinga Newsdesk

February 15, 12:02 PM

HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $69 to $61.

MIRM

1 minute read

SVB Leerink Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $50

By Benzinga Newsdesk

December 14, 4:57 AM

SVB Leerink analyst Mani Foroohar maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $49 to $50.

MIRM

1 minute read

Mirum Pharmaceuticals To Discontinue OHANA Study Of Volixibat Due To Enrollment Feasibility

By Bill Haddad

November 29, 8:31 AM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), today announced the decision to discontinue the OHANA study of volixibat in intrahepatic cholestasis of pregnancy (ICP) due to enrollment feasibility. ICP is a setting of

MIRM

8 minute read

Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday

By Lisa Levin

November 10, 6:12 AM

Gainers

$APE